You are hereHome >
Last week, the Federal Trade Commission announced (news ) that of the complaint) will "pay $5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs – including drugs used to treat breast cancer symptoms and epilepsy – at CVS and Walgreens pharmacies."
CVS Caremark is a powerful intermediary in the Rx business representing the 4-year old merger of the powerful drug store chain CVS and the large Pharmacy Benefits Manager (PBM) Caremark. Last April, Travel Buddy and other leading groups including Consumer Reports/Consumers Union, National Legislative Association on Prescription Drug Prices (NLARx), Community Catalyst and the Consumer Federation of America () urged the Federal Trade Commission to break up the merger because it reduced choice, raised prices and violated patient privacy (more from ).
Along with CFA and NLARx, we have also urged the U.S. courts () not to remove litigation against CVS Caremark into the private, secret arbitration process.
Your donation supports Travel Buddy’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.